Trial Profile
A phase II randomised study to investigate the effects of Bevacizumab on cell proliferation and on pCR in patients with locally advanced operable breast cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 May 2011
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Advanced breast cancer
- Focus Biomarker; Therapeutic Use
- 20 May 2011 New trial record